Short Interest in Adaptimmune Therapeutics plc (NASDAQ:ADAP) Grows By 8.7%

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,500,000 shares, a growth of 8.7% from the December 15th total of 5,060,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the short-interest ratio is presently 2.6 days.

Institutional Trading of Adaptimmune Therapeutics

Several hedge funds have recently added to or reduced their stakes in ADAP. Renaissance Technologies LLC increased its stake in Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company's stock worth $1,742,000 after purchasing an additional 394,566 shares in the last quarter. Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics by 15.6% during the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company's stock worth $12,037,000 after acquiring an additional 1,662,184 shares in the last quarter. Vontobel Holding Ltd. increased its position in shares of Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 30,000 shares in the last quarter. Fullcircle Wealth LLC acquired a new stake in shares of Adaptimmune Therapeutics during the third quarter worth $33,000. Finally, GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics in the 3rd quarter valued at $95,000. Institutional investors and hedge funds own 31.37% of the company's stock.

Adaptimmune Therapeutics Trading Down 1.7 %

Adaptimmune Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $0.58. 621,339 shares of the stock were exchanged, compared to its average volume of 2,349,406. The stock has a market capitalization of $148.38 million, a PE ratio of -2.64 and a beta of 2.24. The company has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.90. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.05.

Analysts Set New Price Targets

ADAP has been the subject of several recent research reports. Guggenheim dropped their price objective on Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday, November 15th. StockNews.com downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 14th. HC Wainwright reduced their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Finally, Mizuho lowered their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating for the company in a report on Wednesday, November 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Adaptimmune Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $2.79.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.